1
|
Buzoianu AD, Sharma A, Muresanu DF, Feng L, Huang H, Chen L, Tian ZR, Nozari A, Lafuente JV, Wiklund L, Sharma HS. Nanodelivery of Histamine H3/H4 Receptor Modulators BF-2649 and Clobenpropit with Antibodies to Amyloid Beta Peptide in Combination with Alpha Synuclein Reduces Brain Pathology in Parkinson's Disease. ADVANCES IN NEUROBIOLOGY 2023; 32:55-96. [PMID: 37480459 DOI: 10.1007/978-3-031-32997-5_2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 07/24/2023]
Abstract
Parkinson's disease (PD) in military personnel engaged in combat operations is likely to develop in their later lives. In order to enhance the quality of lives of PD patients, exploration of novel therapy based on new research strategies is highly warranted. The hallmarks of PD include increased alpha synuclein (ASNC) and phosphorylated tau (p-tau) in the cerebrospinal fluid (CSF) leading to brain pathology. In addition, there are evidences showing increased histaminergic nerve fibers in substantia niagra pars compacta (SNpc), striatum (STr), and caudate putamen (CP) associated with upregulation of histamine H3 receptors and downregulation of H4 receptors in human brain. Previous studies from our group showed that modulation of potent histaminergic H3 receptor inverse agonist BF-2549 or clobenpropit (CLBPT) partial histamine H4 agonist with H3 receptor antagonist induces neuroprotection in PD brain pathology. Recent studies show that PD also enhances amyloid beta peptide (AβP) depositions in brain. Keeping these views in consideration in this review, nanowired delivery of monoclonal antibodies to AβP together with ASNC and H3/H4 modulator drugs on PD brain pathology is discussed based on our own observations. Our investigation shows that TiO2 nanowired BF-2649 (1 mg/kg, i.p.) or CLBPT (1 mg/kg, i.p.) once daily for 1 week together with nanowired delivery of monoclonal antibodies (mAb) to AβP and ASNC induced superior neuroprotection in PD-induced brain pathology. These observations are the first to show the modulation of histaminergic receptors together with antibodies to AβP and ASNC induces superior neuroprotection in PD. These observations open new avenues for the development of novel drug therapies for clinical strategies in PD.
Collapse
Affiliation(s)
- Anca D Buzoianu
- Department of Clinical Pharmacology and Toxicology, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania
| | - Aruna Sharma
- International Experimental Central Nervous System Injury & Repair (IECNSIR), Department of Surgical Sciences, Anesthesiology & Intensive Care Medicine, Uppsala University Hospital, Uppsala University, Uppsala, Sweden
| | - Dafin F Muresanu
- Department of Clinical Neurosciences, University of Medicine & Pharmacy, Cluj-Napoca, Romania
- "RoNeuro" Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania
| | - Lianyuan Feng
- Department of Neurology, Bethune International Peace Hospital, Zhongshan, Hebei Province, China
| | - Hongyun Huang
- Beijing Hongtianji Neuroscience Academy, Beijing, China
| | - Lin Chen
- Department of Neurosurgery, Dongzhimen Hospital, Beijing University of Traditional Chinese Medicine, Beijing, China
| | - Z Ryan Tian
- Department of Chemistry & Biochemistry, University of Arkansas, Fayetteville, AR, USA
| | - Ala Nozari
- Anesthesiology & Intensive Care, Chobanian & Avedisian School of Medicine, Boston University, Boston, MA, USA
| | - José Vicente Lafuente
- LaNCE, Department of Neuroscience, University of the Basque Country (UPV/EHU), Leioa, Bizkaia, Spain
| | - Lars Wiklund
- International Experimental Central Nervous System Injury & Repair (IECNSIR), Department of Surgical Sciences, Anesthesiology & Intensive Care Medicine, Uppsala University Hospital, Uppsala University, Uppsala, Sweden
| | - Hari Shanker Sharma
- International Experimental Central Nervous System Injury & Repair (IECNSIR), Department of Surgical Sciences, Anesthesiology & Intensive Care Medicine, Uppsala University Hospital, Uppsala University, Uppsala, Sweden.
| |
Collapse
|
2
|
Ghazanfari N, van Waarde A, Doorduin J, Sijbesma JWA, Kominia M, Koelewijn M, Attia K, Willemsen ATM, Visser TJ, Heeres A, Dierckx RAJO, de Vries EFJ, Elsinga PH. Pharmacokinetic Modeling of [ 11C]GSK-189254, PET Tracer Targeting H 3 Receptors, in Rat Brain. Mol Pharm 2022; 19:918-928. [PMID: 35170965 PMCID: PMC8905578 DOI: 10.1021/acs.molpharmaceut.1c00889] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
![]()
The histamine H3 receptor has been considered as a target
for the treatment of various central nervous system diseases. Positron
emission tomography (PET) studies with the radiolabeled potent and
selective histamine H3 receptor antagonist [11C]GSK-189254 in rodents could be used to examine the mechanisms of
action of novel therapeutic drugs or to assess changes of regional
H3 receptor density in animal models of neurodegenerative
disease. [11C]GSK-189254 was intravenously administered
to healthy Wistar rats (n = 10), and a 60 min dynamic
PET scan was carried out. Arterial blood samples were obtained during
the scan to generate a metabolite-corrected plasma input function.
PET data were analyzed using a one-tissue compartment model (1T2k),
irreversible (2T3k) or reversible two-tissue compartment models (2T4k),
graphical analysis (Logan and Patlak), reference tissue models (SRTM
and SRTM2), and standard uptake values (SUVs). The Akaike information
criterion and the standard error of the estimated parameters were
used to select the most optimal quantification method. This study
demonstrated that the 2T4k model with a fixed blood volume fraction
and Logan graphical analysis can best describe the kinetics of [11C]GSK-189254 in the rat brain. SUV40–60 and the reference tissue-based measurements DVR(2T4k), BPND(SRTM), and SUV ratio could also be used as a simplified method to
estimate H3 receptor availability in case blood sampling
is not feasible.
Collapse
Affiliation(s)
- Nafiseh Ghazanfari
- University Medical Center Groningen, Department of Nuclear Medicine and Molecular Imaging, University of Groningen, Groningen 9700 RB, The Netherlands
| | - Aren van Waarde
- University Medical Center Groningen, Department of Nuclear Medicine and Molecular Imaging, University of Groningen, Groningen 9700 RB, The Netherlands
| | - Janine Doorduin
- University Medical Center Groningen, Department of Nuclear Medicine and Molecular Imaging, University of Groningen, Groningen 9700 RB, The Netherlands
| | - Jürgen W A Sijbesma
- University Medical Center Groningen, Department of Nuclear Medicine and Molecular Imaging, University of Groningen, Groningen 9700 RB, The Netherlands
| | - Maria Kominia
- University Medical Center Groningen, Department of Nuclear Medicine and Molecular Imaging, University of Groningen, Groningen 9700 RB, The Netherlands
| | | | - Khaled Attia
- University Medical Center Groningen, Department of Nuclear Medicine and Molecular Imaging, University of Groningen, Groningen 9700 RB, The Netherlands
| | - Antoon T M Willemsen
- University Medical Center Groningen, Department of Nuclear Medicine and Molecular Imaging, University of Groningen, Groningen 9700 RB, The Netherlands
| | | | | | - Rudi A J O Dierckx
- University Medical Center Groningen, Department of Nuclear Medicine and Molecular Imaging, University of Groningen, Groningen 9700 RB, The Netherlands
| | - Erik F J de Vries
- University Medical Center Groningen, Department of Nuclear Medicine and Molecular Imaging, University of Groningen, Groningen 9700 RB, The Netherlands
| | - Philip H Elsinga
- University Medical Center Groningen, Department of Nuclear Medicine and Molecular Imaging, University of Groningen, Groningen 9700 RB, The Netherlands
| |
Collapse
|